Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern P L
Dept of Analisis Clínicos e Immunología, Hospital Virgen de las Nieves, Universidad de Granada, Spain.
Immunol Today. 1993 Oct;14(10):491-9. doi: 10.1016/0167-5699(93)90264-L.
HLA expression is frequently altered in tumours compared to the tissue from which they originate. Given the central role of MHC products in the restriction of T-cell recognition, regulation of tumour HLA expression might be a strategy for the evasion of immune surveillance by the malignant cells. Federico Garrido, Peter Stern and colleagues present data from a variety of tumour types, suggesting that HLA class I alterations may occur at a particular step between the development of an in situ lesion and an invasive carcinoma.
与肿瘤起源的组织相比，肿瘤中的人类白细胞抗原（HLA）表达常常发生改变。鉴于主要组织相容性复合体（MHC）产物在限制T细胞识别中起核心作用，调节肿瘤HLA表达可能是恶性细胞逃避免疫监视的一种策略。费德里科·加里多、彼得·斯特恩及其同事展示了来自多种肿瘤类型的数据，表明HLA I类分子的改变可能发生在原位病变发展为浸润性癌的特定阶段。
